From: Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
Reference | Agent administered | Number of subjects | Response(%) | Clinical benefit(%) | Time to progression(months) |
---|---|---|---|---|---|
[9] | Letrozole | 453 | 30 | 49 | 9.4 |
 | Tamoxifen | 454 | 20 | 38 | 6.0 |
[13] | Letrozole | 154 | 55 | - | - |
 | Tamoxifen | 170 | 36 | - | - |
[11] | Anastrozole | 171 | 21 | 59 | 11.1 |
 | Tamoxifen | 182 | 17 | 46 | 5.6 |
[19] | Anastrozole | 340 | 33 | 56 | 8.2 |
 | Tamoxifen | 328 | 33 | 56 | 8.3 |
[11] | Anastrozole | 121 | 43 | 83 | - |
 | Tamoxifen | 117 | 31 | 56 | - |
[10] | Exemestane | 61 | 41 | 57 | - |
 | Tamoxifen | 59 | 17 | 42 | - |